Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

This is less a legal headline than a credibility event. If the channel-inventory allegation is even partially right, the market is likely underpricing a multi-quarter reset: reported growth was not purely organic, so the next leg is usually slower sell-in, lower reorder cadence, and some mix of rebate/price concessions to clear the pipeline. For a company with concentration in one flagship product, that can compress both EV/Sales and forward multiple faster than the absolute revenue miss would suggest.

The second-order effect is on the category, not just the name. Competitors with cleaner demand signals can win incremental share if hospitals and distributors de-risk supplier relationships, and peers in plasma-derived therapies may get a relative rerating if investors start questioning the quality of growth across small-cap specialty biologics. The most vulnerable near-term line items are gross margin and working capital, because any prior pull-forward usually reverses first in receivables and inventory before it shows up cleanly in the P&L.

The contrarian point is that this type of announcement is often a plaintiff-advertising overhang rather than evidence. The stock may overshoot lower in days, then rebound if upcoming filings show stable end-market demand, flat DSO, and no abnormal inventory build. What falsifies the bearish case is sequential volume stability and no deterioration in customer concentration or gross-to-net disclosures over the next 1-2 reporting cycles; absent that, the thesis is a 1-3 month revenue air pocket and 6-18 month multiple compression problem.